To summarize the evidence of an association between obesity and breast cancer prognosis.
INTRODUCTION
Obesity is currently an epidemic, with 69% of adults in the United States and 38% in the world being either overweight or obese. [1] [2] [3] Obesity is associated with an altered whole-body physiology and hormonal environment that promote a number of disease states, including diabetes and cardiovascular disease. Obesity is also associated with an increased risk of developing a number of cancers and with poorer survival outcomes for patients with those cancers. 4 Here we review the evidence of the relationship between obesity and breast cancer, with an emphasis on breast cancer prognosis. This review is not intended to be comprehensive but rather to provide an overview and to highlight important recent findings. We emphasize results from larger studies, clinical trials, and meta-analyses from the past 5 to 10 years. The reader is referred to prior reviews for further information. 5, 6 We apologize to colleagues whose work could not be included because of space limitations.
OBESITY AND BREAST CANCER RISK
Although our focus is on breast cancer outcomes, understanding associations of body size with the risk of developing breast cancer sheds light on the body habitus of women at the time of breast cancer diagnosis. It has long been recognized that overweight and obesity (and adult weight gain) are associated with an increased risk of postmenopausal breast cancer, notably hormone receptor-positive cancers (risk estimate, 1.82; 95% CI, 1.55 to 2.14 for overweight and obese combined). 7 In contrast, overweight and obesity have been thought to be associated with a lower risk of premenopausal breast cancer, and that remains true for hormone receptor-positive cancers (risk estimate, 0.80; 95% CI, 0.70 to 0.92 for overweight and obese combined). 7 However, recent evidence has demonstrated an increased risk of triple-negative breast cancers (TNBCs) in obese premenopausal women (odds ratio, 1.43; 95% CI, 1.23 to 1.65). 8 Physical inactivity, an attribute linked to obesity, has been associated with higher risk of breast cancer regardless of menopausal status. 9 Thus, many women with breast cancer are heavier and more physically inactive than the general population at the time of diagnosis. This underscores the importance of the adverse associations of obesity with breast cancer outcomes that are discussed in this article.
OBESITY AND BREAST CANCER PROGNOSIS
Several recent meta-analyses have examined the relationship between body mass index (BMI) and survival in large numbers of patients (Table 1) . A meta-analysis by Protani et al 10 included 43 studies of patients with breast cancer diagnosed between 1963 and 2005. The pooled hazard ratios (HRs) comparing obese versus nonobese patients were 1.33 (95% CI, 1.21 to 1.47) for overall survival (OS) and 1.33 (95% CI, 1.19 to 1.50) for breast cancer-specific survival (BCSS) and were statistically significant. This association was maintained after adjusting for age and stage and regardless of menopausal status, year of diagnosis, or study type (treatment or observational). A subsequent meta-analysis by Niraula et al 11 found that the association of obesity (obese v nonobese) with breast cancer outcomes (OS and BCSS) did not differ by menopausal or hormone receptor status.
The most recent meta-analysis, by Chan et al, 12 is also the most extensive, involving 213,075 patients from 82 studies, with large numbers of events (41,477 deaths, including 23,182 resulting from breast cancer). The investigators examined total mortality and breast cancer-specific mortality, classifying BMI at baseline and after diagnosis into four categories (underweight, normal weight, overweight, and obese). The summary relative risks (RRs) for total mortality and breast cancer-specific mortality for obese versus normal-weight patients at baseline were 1.41 (95% CI, 1.29 to 1.53) and 1.35 (95% CI, 1.24 to 1.47), respectively. These positive associations were present when BMI was measured 12 months before or 12 months or more after diagnosis. They were also present regardless of menopausal status, with a suggestion of larger effects in premenopausal versus postmenopausal patients (RR, 1.75 v 1.34). The RRs for total mortality and breast cancer-specific mortality for overweight versus normal-weight patients at baseline were lower, at 1.07 (95% CI, 1.02 to 1.12) and 1.11 (95% CI, 1.06 to 1.17), respectively, but were still statistically significant. Dose-response meta-analysis revealed a nonlinear J-shaped curve for total mortality, with RRs increasing not only for overweight or obese but also for underweight patients. In contrast, and importantly, this analysis revealed evidence only for a linear relationship for breast cancer-specific mortality. Linear models (excluding the small proportion of underweight patients) gave RRs for each 5-kg/m 2 increase in BMI of 1.17 and 1.18 for total mortality and breast cancer-specific mortality, respectively.
A number of studies have shown that obese patients present with larger tumors and, less consistently, with increased lymph node metastases and higher-grade tumors. [13] [14] [15] Although the higher T and N stages may reflect delayed diagnosis in obese women, they, along with higher grade, may also reflect more aggressive biology in obesity, leading to higher risk of recurrence. In support of this, after adjusting for these tumor factors, overweight and obesity remain independent risk factors for decreased BCSS and OS. In a large study of 18,967 patients from Denmark, Ewertz et al 15 demonstrated that overweight and obese patients had an increased risk of distant, but not local, recurrence. The increased risk of distant recurrence was significant only in years 5 to 10, with HRs of 1.42 (95% CI, 1.17 to 1.73) and 1.46 (95% CI, 1.11 to 1.92) for overweight and obese patients, respectively; this translated into an increased risk of breast cancer-related death primarily after 10 years. Goodwin et al 16 reported that higher BMI was associated with an increased risk of both early (first 5 years) and late (beyond 5 years) distant recurrences and death. An association of obesity (BMI $ 30 kg/m 2 ) with increased late recurrence and mortality in estrogen receptor-positive breast cancer was also reported in 6,295 patients from the After Breast Cancer Pooling Project. 17 Similar patterns have been identified in other studies. 18, 19 In summary, meta-analyses involving large numbers of patients have provided evidence that obesity is associated with an increased risk of recurrence and death of approximately 35% to 40%. This seems to be true after adjusting for tumor-related variables and regardless of menopausal or hormone receptor status. Overweight and obesity also seem to be associated with distant and late recurrences. Of interest, in a recent meta-analysis, weight gain after breast cancer diagnosis was associated with a modest increased risk of all-cause mortality but not with increased breast cancer-specific mortality. 20 Adverse effects on allcause mortality were greatest when weight gain was greater than 10%, suggesting that BMI at diagnosis may be the most relevant predictor of breast cancer outcome.
OBESITY AND BREAST CANCER SUBTYPES
There is evidence that the relationship between obesity and breast cancer prognosis varies according to breast cancer subtype. The data for an association between BMI and decreased survival are fairly consistent for ER-positive breast cancer (as summarized in the previous section), with less consistent results reported for the other subtypes. This may in part relate to the approach used to classify breast cancer subtypes, and the current reliance on immunohistochemical staining of ER, progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) to define subtypes may not be optimal. One recent study reported that associations of BMI with worse breast cancer outcomes were independent of PAM50-defined breast cancer subtype (eg, luminal A or B, HER2 enriched, basal-like). 21 
ER-Negative and TNBCs
The data for an association between BMI and decreased survival in ER-negative or TNBC are inconsistent, with some studies showing an association 11,22-26 and others not 27-36 (Table 2 ). 25 In an analysis of pooled German neoadjuvant trials involving 8,872 patients, obese and very obese patients in the TNBC subset had significantly decreased disease-free survival (DFS) and OS. Another recent large study (the SUCCESS-A trial, which randomly assigned women to different adjuvant chemotherapy regimens; N = 3,754) reported high BMI was associated with poorer DFS and OS in TNBC but not other breast cancer subtypes. 24 In contrast, several reports nested in randomized controlled trials of systemic therapy failed to identify prognostic associations of obesity in ERnegative or TNBC ( Table 2 ).
There are several potential explanations for these variable results: there may be no true association of obesity with prognosis, or there may be an association, but it may be difficult to detect. There are a number of reasons for the latter possibility. Demonstration of an association may be dependent on study design, adjuvant treatment administered, or specific population studied, making it challenging to identify consistently across heterogeneous studies. The postulated effect sizes of obesity on breast cancer prognosis are modest, and associations may be difficult to observe in small studies. At the molecular level, TNBC is not as common as other breast cancer subtypes and comprises at least seven molecular subtypes, each of which may have differing obesity associations. Heterogeneity in study approaches in terms of definition of subtypes (using full ER, PR, or HER2 status v ER [6 PR] status alone), in handling of BMI in statistical analyses (categorical [with two v $ three categories] v continuous; handling BMI as a continuous variable will enhance power), and in definitions of outcomes (breast cancer or overall mortality) and in treatments received (anthracycline v nonanthracycline chemotherapy) may all contribute to inconsistent findings. Evaluation of obesity associations in systemic therapy trials, particularly those including cardiotoxic drugs, may lead to under-representation of women with obesity-associated metabolic factors (eg, high insulin or glucose, systemic inflammation) that may mediate the associations of obesity with breast cancer outcomes, further reducing power.
Nevertheless, the recent positive results highlighted in our article lend support to an association of obesity with worse outcomes in at least a subset of patients with TNBC. Furthermore, animal studies have demonstrated that obesity promotes TNBC progression and therefore provide a compelling biologic argument that this effect is real (Jiralerspong et al, manuscript in preparation). [37] [38] [39] Consistent with these observations, in WINS (Women's Intervention Nutrition Study), a low-fat diet leading to modest weight loss was associated with improved OS in patients with ERand/or PR-negative disease (and presumably TNBC).
40,41 A metaanalysis of available studies examining associations of obesity with outcome in TNBC may be of value; it would include larger numbers of patients with TNBC, could compare multiple categories of BMI or model associations across BMI as a continuous variable, and potentially stratify by treatment.
HER2-Positive Breast Cancer
The relationship between BMI and HER2-positive breast cancer is also unclear (Table 2) . 28, 30, 32, [42] [43] In the pretrastuzumab era, a study of 1,250 patients reported obese (BMI . 30 kg/m 2 ) patients with ER-negative, HER2-positive disease had worse OS (HR, 1.79; 95% CI, 1.03 to 3.10) and distant metastases (HR, 2.03; 95% CI, 1.13 to 3.63) compared with normal-weight patients, whereas there were no significant obesity associations in patients with ER-positive, HER2-positive disease. 42 In contrast, a study that did not stratify by ER status found no differences in survival by BMI for patients with HER2-positive disease. 27 In the trastuzumab era, the North Central Cancer Treatment Group N9831 trial reported worse DFS (but did not examine OS) in the pooled analysis of all treatment arms combined, in both overweight (HR, 1.30; 95% CI, 1.06 to 1.61) and obese (HR, 1.31; 95% CI, 1.07 to 1.59) versus normal-weight patients. 43 In contrast, the related National Surgical Adjuvant Breast and Bowel Project B-31 trial identified no differences in OS or recurrence by baseline BMI, 30 similar to HER2-subset analyses in other studies. 28, 32 Both N9831 and B-31 showed no differences in survival by BMI within any single treatment arm (either nontrastuzumab or trastuzumab containing). Taken together, these data do not provide strong evidence that obesity is associated with worse survival outcomes in patients with HER2-positive disease; it is possible that obesity associations may be more salient in those who do not receive trastuzumab. Larger and/or pooled studies should be conducted to address the relationship between BMI and survival in patients with HER2-positive disease, taking into account ER status and whether these effects are modified by trastuzumab or other HER2-directed therapies.
OBESITY AND AROMATASE INHIBITOR THERAPY
Because obesity is associated with elevated aromatase activity and serum estrogen levels in postmenopausal women, it is possible that obesity modulates responses to endocrine therapy. The most important evidence comes from clinical trials comparing adjuvant aromatase inhibitor (AI) with tamoxifen therapy (Table 3) . 18, 19, [44] [45] [46] In postmenopausal patients, there is evidence of differential effects of anastrozole (v tamoxifen) in overweight or obese versus normal-weight patients. In the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial, the relative benefit of anastrozole over tamoxifen for total and distant recurrences was seen in normal-weight but not obese (BMI . 30 kg/m 2 ) women. 18 In the Austrian Breast and Colorectal Cancer Study Group 6a trial, the benefit of extended adjuvant anastrozole over no further therapy was present in normal-weight but not overweight or obese (combined) women. 45 In premenopausal patients, a similar pattern was seen in the Austrian Breast and Colorectal Cancer Study Group 12 trial, in which anastrozole plus goserelin led to greater risks of recurrence (HR, 1.49; 95% CI, 0.93 to 2.38) and death (HR, 3.03; 95% CI, 1.35 to 6.82) in overweight and obese women (combined) when compared with tamoxifen plus goserelin; DFS and OS were similar in normalweight women receiving either treatment. 46 The effects of BMI on outcomes in TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial), which investigated exemestane versus tamoxifen plus ovarian suppression, have not been reported, 47, 48 although it has been reported that higher BMI is associated with a higher likelihood of elevated estradiol during treatment. 49 In contrast, in the Breast International Group 1-98 trial, there was no evidence that the benefit of letrozole over tamoxifen differed in postmenopausal obese (BMI $ 30 kg/m 2 ) versus normal-weight women, in terms of DFS, OS, or distant recurrence-free interval. 19 In combination with the studies we have already discussed, this suggests that letrozole may be more effective than anastrozole in obese patients. However, an unpublished report of the FACE (Femara versus Anastrozole Clinical Evaluation) trial comparing letrozole versus anastrozole in postmenopausal patients with node-positive disease found no differences in DFS or OS according to BMI. 50 In a recent systematic review, a trend for a negative effect of obesity on AI efficacy in postmenopausal women was identified, but the size of the effect was unclear. 51 The potential for differential effects of different AIs was not examined. One hypothesis for the different results of letrozole versus anastrozole is differential suppression of estrogens by the AIs. Indeed, letrozole is known to be a more potent inhibitor of aromatase than anastrozole, 52,53 and one study reported that 3 months of letrozole suppressed plasma estrogen levels to lower absolute levels than anastrozole across all BMI categories. 54 Some studies have shown modestly increased estradiol levels for obese versus normal-weight patients receiving AIs, 54-56 but others have not. 57, 58 Whether circulating estrogens (eg, estradiol, estrone, estrone sulfate) or surrogate hormones (eg, follicle-stimulating hormone) can serve as markers for endocrine therapy response in obese patients should be evaluated in prospective trials.
POTENTIAL BIOLOGIC MECHANISMS LINKING OBESITY AND BREAST CANCER OUTCOMES
There is a strong biologic basis for an association of obesity with poor breast cancer outcomes, as discussed elsewhere in this Journal of Clinical Oncology (JCO) special series and in prior reviews. 4, [59] [60] [61] Table 4 summarizes points of interest in breast cancer.
INTERVENTIONS
Although obesity is associated with poor outcomes in women with breast cancer, it is not clear whether postdiagnosis weight loss (resulting from changes in caloric intake, physical activity, or other interventions) will reverse this effect. There are several potential reasons for this. 63 It remains possible that obesity is not causally associated with outcomes; in this case, weight loss will not affect outcomes. If obesity is causally associated with outcomes, biologic effects of obesity may be fixed at diagnosis (ie, obese women may have more proliferative or aggressive tumors, characteristics that may not change with weight loss). Alternatively, the degree of weight loss possible with available lifestyle interventions (typically 5% to 7%) may not be sufficient to alter outcomes. Randomized trials will be needed to differentiate these possibilities.
Diet and Physical Activity
Interventions based on diet and physical activity in breast cancer are reviewed elsewhere in this JCO special series. Here we discuss two dietary intervention adjuvant trials for which there are long-term survival outcomes. The WINS trial randomly assigned 2,437 patients with breast cancer to a low-fat diet (target 15% fat calories, aggressive dietary counseling, and follow-up) versus control (minimal dietary counseling). 40 In the final analysis, 41 a significant improvement in OS in the ER-and PR-negative subset was seen, with an HR of 0.36 (95% CI, 0.18 to 0.74; P = .003). Nonsignificant improvements were seen in the ER-and PR-positive subset and the entire cohort. The WHEL (Women's Healthy Eating and Living) trial randomly assigned 3,088 patients to a diet high in vegetables, fruit, and fiber and low in fat (15% to 20% fat calories, telephone counseling, cooking classes offered) versus control (diet guidelines, no counseling, fewer cooking classes) up to 4 years postdiagnosis (a design that excluded women with early recurrences). 64 There was no difference in DFS or OS between intervention and control groups.
The conflicting results of the WINS and WHEL trials may reflect differences in patient populations (younger and more premenopausal in WHEL), tumor characteristics (larger and more node positive in WHEL), and interventions delivered (low-fat diet alone in WINS v low-fat diet plus high-fruit, -vegetable, and -fiber diet in WHEL), as well as cancer-associated therapies 
Mechanism
In patients with breast cancer, multiple metabolic and adipose tissue factors associated with obesity (eg, insulin, glucose, and adipokines such as, leptin, crown-like structures of inflammatory cells surrounding dying adipocytes in adipose tissue) have been associated with both obesity and poor outcomes Insulin, in particular, has received considerable attention; Goodwin et al 16, 62 reported a strong association of fasting insulin with poor breast cancer outcomes in nondiabetic women; this association was subsequently shown to be strongest in first 5 years after diagnosis Because breast cancer cells commonly express insulin receptors (typically the fetal form), insulin can bind to those receptors (which may hybridize with IGF-1 receptors to bind IGF-1 as well) to activate signaling through PI3K/Akt and Ras/MAPK pathways, leading to increased proliferation and reduced apoptosis (more chemotherapy, less endocrine therapy in WHEL, reflecting more advanced tumor stage). 65 The earlier time of enrollment (all patients enrolled within year 1 after diagnosis in WINS v most patients in years 1 to 4 in WHEL, which may have precluded capture of early events, particularly in ER-negative cancers), larger decrease in percentage of fat calories, and greater adherence achieved (in WINS) might have contributed to the beneficial effects on recurrence rates in WINS. Additionally, a modest decrease in weight (average loss of approximately 6 lbs maintained over 5 years) in WINS but not WHEL may have contributed to the different outcomes.
Recently, Chlebowski et al 66 reported the long-term effects of dietary fat reduction on breast cancer risk and outcomes postdiagnosis in the WHI (Women's Health Initiative) randomized prevention trial of dietary fat reduction versus no dietary change. Women in the intervention arm reported lower fat intake, higher fruit, vegetable, and grain intake, and a modest amount of weight loss. The risk of breast cancer was significantly lower in the intervention arm (HR, 0.68), and deaths after breast cancer diagnosis were significantly reduced (HR, 0.65). These results are encouraging because they suggest an intervention that modified diet and is associated with modest weight loss may be beneficial in lowering breast cancer deaths. However, because the intervention was started before breast cancer diagnosis, it cannot be assumed that dietary modification and/or weight loss after breast cancer diagnosis will have similar effects.
As reviewed elsewhere in this JCO special series, numerous studies have demonstrated that weight loss, achieved through diet, physical activity, and behavior modification (based on counseling, either in-person or telephone, individual or group), is feasible after breast cancer diagnosis. [67] [68] [69] [70] [71] A recent systematic review reported most interventions led to weight loss of 5% or greater at 2 to 18 months, without serious adverse events. 68 What remains unknown is whether weight loss achieved via lifestyle interventions will improve survival and in which patient subsets or breast cancer subtypes, so additional studies are needed. One such study is the BWEL (Breast Cancer Weight Loss) trial, which will randomly assign more than 3,300 overweight or obese patients with HER2-negative disease to a telephone-based weight loss intervention versus health education and examine survival outcomes and correlative science. Similar lifestyle intervention trials are under way in Italy and Germany. The Italian DIANA-5 (Diet and Androgens) trial has randomly assigned patients with a high risk of recurrence (ER negative or ER positive with metabolic syndrome, high insulin or testosterone) to an intervention based on Mediterranean and macrobiotic diet, in association with moderate physical activity, versus control. 72 The German SUCCESS-C trial has randomly assigned pre-and postmenopausal patients with HER2-negative disease to a low-fat diet high in fruits, vegetables, and whole grains, with increased physical activity, versus control. 73 Both trials will examine relevant biomarkers as well as survival outcomes and are due to report in the near future.
Several dietary strategies are available for weight loss, based on relative fat, carbohydrate, and protein content. Although this is a rapidly evolving area, current evidence suggests that there are no significant differences in terms of weight loss between diets based on low versus high fat, low versus high carbohydrates, or low versus high protein. 74 This is supported by meta-analyses. 75, 76 A Mediterranean diet is also an effective option for weight loss. 77 The impact of these different dietary approaches on breast cancer outcomes remains to be fully evaluated. As discussed in our article, most breast cancer trials to date have used a low-fat diet approach, with the pending DIANA-5 trial using a Mediterranean diet.
Metformin and Other Interventions
Preclinical and clinical evidence has suggested that the diabetes drug metformin may have antitumor activity in breast cancer, [78] [79] [80] leading to a number of clinical trials of metformin in breast cancer. [81] [82] [83] The largest of these trials, the ongoing National Cancer Institute of Cancer MA.32 randomized adjuvant trial of metformin versus placebo involving 3,649 women, is nearing completion. Although not a weight loss intervention trial, early analyses showed that metformin improved many of the potential physiologic mediators of obesity effects in breast cancer (eg, insulin, glucose, homeostasis model assessment, leptin, highsensitivity C-reactive protein) independently of baseline insulin or BMI. 84 Furthermore, metformin was associated with modest weight loss (3% difference between metformin and placebo arms at 6 months). As a result, it is anticipated that the findings of MA.32 may shed light on the impact of postdiagnosis metabolic change (including that resulting from weight loss) on breast cancer outcomes.
Bariatric surgery and recently approved weight loss medications may promote greater weight loss than is seen with lifestyle interventions, as discussed elsewhere in this JCO special series. The safety and impact of these interventions on breast cancer outcomes are unknown. For example, for the obesity drug liraglutide, there was a nonsignificant numeric difference in the number of new breast cancer cases (drug, 10 v placebo, three), which was postulated to be the result of enhanced detection of existing cancers in women who lost weight; no information was provided on breast cancer survival. 85, 86 Longer-term follow-up will be needed for this and other recently approved obesity medications.
CLINICAL MANAGEMENT OF OBESE PATIENTS WITH BREAST CANCER
Surgery, Chemotherapy, and Endocrine Therapy Clinical management considerations relevant to surgery, chemotherapy, and endocrine therapy in obese patients are summarized in Table 5 .
Weight and Lifestyle
Although obesity is associated with inferior outcomes in breast cancer, it is not clear whether this is the case for all subtypes of breast cancer, nor is it established whether weight loss (via diet, physical activity, surgical procedures, or drug therapies) will reverse this effect. Studies to obtain this information are under way. At least two studies (WINS and WHI) have reported that dietary fat reduction (before or within 1 year of diagnosis) associated with modest weight loss may lead to improved breast cancer outcomes. Until additional data are available, it is reasonable to counsel patients to maintain a healthy weight or lose the 5% to 7% that is expected with lifestyle interventions and to follow current diet and physical activity guidelines for cancer survivors (Table 6) . 96, 97 Physical activity has been incorporated into these guidelines not only because it can contribute to weight management but also because higher levels of physical activity (pre-or postdiagnosis) have been associated with improved outcomes in observational studies. 98 In the absence of high-level evidence, it should be made clear that the rationale for maintaining a healthy weight is for general (noncancer) health benefits and that benefits in terms of improving breast cancer outcomes are not established and are under evaluation.
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THE PATH FORWARD
As reviewed in our article, a large body of evidence now supports an association between obesity and an increased risk of breast Obesity is a risk factor for complications after mastectomy, 87, 88 either alone or in combination with immediate breast reconstruction, whether implant based or autologous [87] [88] [89] Complications include surgical site complications (eg, infections, wound dehiscence, and prosthetic and flap loss) and systemic medical complications (eg, VTE and pneumonia) Morbidly obese patients (class III; BMI . 40 kg/m 2 ) are at particularly elevated risk for these complications 90 Risk of VTE in obese patients is procedure dependent, increasing from 0.4% to 0.8% to 1.8% for mastectomy to implant to autologous reconstruction 91 Obesity is also a risk factor for lymphedema after breast cancer surgery, with risk estimates up to 5.5-fold higher 92 This information can be incorporated into surgical risk counseling and management; for instance, the incidence of VTE after implant-based reconstruction is approximately 1% and that after autologous reconstruction is approximately 2%, so consideration of prophylactic anticoagulants may be reasonable Chemotherapy Chemotherapy dosing in obese patients has been recently reviewed, and we summarize key points here 93, 94 Obese patients with cancer should receive full weight-based chemotherapy doses calculated using their actual body weight, especially when the goal is cure There is no evidence to suggest increased hematologic or nonhematologic toxicity with such dosing In contrast, there is evidence to support poorer survival outcomes (DFS, OS) with underdosing of chemotherapy In the event of dose reductions, considerations for resumption of full weight-based dosing should be the same as those for nonobese patients Fixed dosing (independent of body weight or BSA) should be considered for certain chemotherapy agents (eg, carboplatin) Overweight and obesity have recently been associated with higher risk of cardiotoxicity after treatment with trastuzumab in women with HER2-positive breast cancer 95 Close monitoring and effective management of cardiac risk factors (eg, blood pressure, cholesterol, smoking) should be considered in these patients Endocrine therapy
Concerns have been raised about the relationship between BMI and AI adjuvant therapy benefit (see Obesity and Aromatase Inhibitor Therapy) Available evidence suggests that anastrozole may be associated with inferior outcomes (v tamoxifen) in both post-and premenopausal patients who are obese; this was not found to be true for letrozole (v tamoxifen) in postmenopausal obese patients For postmenopausal patients, data from the BIG 1-98 trial support use of letrozole and data from ATAC and ABCSG-6a trials raise concerns regarding use of anastrozole As a result, because of potentially increased efficacy but equivalent tolerability, it is reasonable to use letrozole rather than anastrozole in obese postmenopausal patients For premenopausal patients, the current standard of care from TEXT and SOFT trials is to use exemestane plus ovarian suppression when indicated for aggressive disease; in the absence of further evidence to contrary, we believe this is acceptable for obese patients Additional data directly comparing different AIs in obese patients is pending It is recommended that clinicians counsel survivors to achieve and maintain healthy weight and if overweight or obese to limit consumption of high-calorie foods and beverages and increase physical activity to promote and maintain weight loss Physical activity It is recommended that clinicians counsel survivors to engage in regular physical activity consistent with the ACS guideline 96 and specifically avoid inactivity and return to normal daily activities as soon as possible after diagnosis, aim for $ 150 minutes of moderate or 75 minutes of vigorous aerobic exercise per week, and include strength training exercises $ 2 days per week and emphasize strength training for women treated with adjuvant chemotherapy or hormone therapy Nutrition It is recommended that clinicians counsel survivors to achieve a dietary pattern that is high in vegetables, fruits, whole grains, and legumes; low in saturated fats; and limited in alcohol consumption cancer recurrence and death. However, a number of challenges remain:
• Better defining the relationship between obesity and prognosis in different breast cancer subtypes, particularly TNBC and HER2-positive breast cancer.
• Understanding the biologic mechanisms in all subtypes.
• Evaluating whether weight loss and lifestyle interventions will improve outcomes.
• Developing obesity-targeted biologic therapies and evaluating whether they will improve outcomes.
There are 247,000 new cases of breast cancer in the United States each year and 1.7 million in the world. Approximately 70% of these patients in the United States and 40% in the world are at increased risk for breast cancer recurrence and death because of obesity. The magnitude of this effect (35% to 40% increased risk) suggests that obesity may cancel the benefit of our best breast cancer therapies. Thus, overcoming these challenges represents a tremendous opportunity to improve the care and outcomes of obese patients with breast cancer and to impact public health positively.
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